Temozolomid in der Behandlung maligner Gliome

Thomas Hundsberger, Dorothee Koch, Sven Klimpe & Uwe Schlegel

Temozolomide is an orally administered, alkylating agent with approval for recurrent and progressive malignant gliomas. Here we review the pharmacological properties of temozolomide, its possible side effects and current indications for the treatment of malignant gliomas. Some current treatment trials on temozolomide are discussed, which may have an impact on its role in future Neuro-Oncology.

**type**
journal paper/review (Deutsch)

**date of publishing**
2003

**journal title**
Aktuelle Neurologie (30)

**pages**
184-187